Alto Neuroscience (NYSE:ANRO) Trading 8.8% Higher - Here's What Happened

Key Points

• Alto Neuroscience (ANRO) shares jumped about 8.8% Monday to $24.78, trading 167,857 shares — roughly 34% below its average session volume.
• The stock carries a consensus analyst rating of "Moderate Buy" with a consensus price target of $35.14, though recent research notes were mixed with several target adjustments and varying buy/hold/sell stances.
• Alto beat quarterly expectations with EPS of -$0.45 vs. a -$0.56 consensus and is a clinical-stage biotech using a digital neuroscience platform (EEG, cognition, PROs) to predict treatment response in neuropsychiatric disorders.

Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) shares traded up 8.8% during mid-day trading on Monday . The stock traded as high as $24.61 and last traded at $24.78. 167,857 shares traded hands during trading, a decline of 34% from the average session volume of 254,385 shares. The stock had previously closed at $22.78.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Robert W. Baird cut their price target on Alto Neuroscience from $41.00 to $38.00 and set an "outperform" rating on the stock in a research note on Thursday, April 2nd. Wall Street Zen lowered Alto Neuroscience from a "hold" rating to a "sell" rating in a research note on Saturday, March 21st. JonesTrading cut their target price on Alto Neuroscience from $49.00 to $44.00 and set a "buy" rating on the stock in a research note on Thursday, April 2nd. BTIG Research increased their target price on Alto Neuroscience from $27.00 to $28.00 and gave the company a "buy" rating in a research note on Tuesday, February 17th. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of Alto Neuroscience in a research note on Monday, December 29th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $35.14.

Alto Neuroscience Stock Up 13.1%

The firm has a fifty day simple moving average of $19.90 and a 200-day simple moving average of $15.60. The company has a market capitalization of $823.19 million, a P/E ratio of -11.79 and a beta of 2.01. The company has a quick ratio of 15.69, a current ratio of 15.69 and a debt-to-equity ratio of 0.12.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last announced its quarterly earnings results on Monday, March 16th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.11. On average, equities research analysts expect that Alto Neuroscience, Inc. will post -2.54 EPS for the current fiscal year.

Institutional Investors Weigh In On Alto Neuroscience

Several large investors have recently modified their holdings of ANRO. AQR Capital Management LLC bought a new stake in shares of Alto Neuroscience in the first quarter worth about $52,000. Torren Management LLC bought a new stake in shares of Alto Neuroscience in the fourth quarter worth about $62,000. Invesco Ltd. bought a new position in shares of Alto Neuroscience during the first quarter worth about $67,000. Vanguard Personalized Indexing Management LLC grew its holdings in shares of Alto Neuroscience by 13.7% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 17,045 shares of the company's stock worth $69,000 after buying an additional 2,055 shares in the last quarter. Finally, Bridgeway Capital Management LLC grew its holdings in shares of Alto Neuroscience by 85.9% during the second quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company's stock worth $119,000 after buying an additional 25,000 shares in the last quarter.

Alto Neuroscience Company Profile

Alto Neuroscience NYSE: ANRO is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto's proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.